WuXi STA’s API site receives FDA nod following first inspection

12:45 EDT 7 May 2018 | DecisionNewsMedia

WuXi STA has passed its first FDA inspection at its active pharmaceutical ingredient (API) development and manufacturing facility located in Changzhou, China.

Original Article: WuXi STA’s API site receives FDA nod following first inspection

More From BioPortfolio on "WuXi STA’s API site receives FDA nod following first inspection"